Skip to Main Content
Table 1

Characteristics of Subjects

Normal subjects  n = 9 (5 M, 4 F)   
  Age 39.4 ± 5.8 yr*   
Total number of hepatitis C patients  n = 26 (17 M, 9 F)   
  Chronic hepatitis (18)   
  Chronic hepatitis with cirrhosis (8)   
Hepatitis C patients not on IFN-α treatment (never treated or  blood sampled before started on IFN-α treatment)  n = 18 (14 M, 4 F)   
  Age 43.8 ± 10.5 yr   
Hepatitis C patients on IFN-α treatment  n = 15 (10 M, 5 F)   
  Age 40.7 ± 10.5 yr   
  3 to 10 million units IFN-α three times/wk   
  1–40 wk of treatment   
  26.4 ± 12.0 h from last injection  until blood draw   
Serum IFN-α levels  Normal subjects:  13.8 ± 0.2 pg/ml 
  Hepatitis C:  14.5 ± 0.8 pg/ml 
  Hepatitis C on IFN-α:  34.0 ± 13.9 pg/ml 
Normal subjects  n = 9 (5 M, 4 F)   
  Age 39.4 ± 5.8 yr*   
Total number of hepatitis C patients  n = 26 (17 M, 9 F)   
  Chronic hepatitis (18)   
  Chronic hepatitis with cirrhosis (8)   
Hepatitis C patients not on IFN-α treatment (never treated or  blood sampled before started on IFN-α treatment)  n = 18 (14 M, 4 F)   
  Age 43.8 ± 10.5 yr   
Hepatitis C patients on IFN-α treatment  n = 15 (10 M, 5 F)   
  Age 40.7 ± 10.5 yr   
  3 to 10 million units IFN-α three times/wk   
  1–40 wk of treatment   
  26.4 ± 12.0 h from last injection  until blood draw   
Serum IFN-α levels  Normal subjects:  13.8 ± 0.2 pg/ml 
  Hepatitis C:  14.5 ± 0.8 pg/ml 
  Hepatitis C on IFN-α:  34.0 ± 13.9 pg/ml 
*

Mean ± SD.  

P <0.04. M, male; F, female.  

Close Modal

or Create an Account

Close Modal
Close Modal